SCHEMBL25118011

SCHEMBL25118011

CCOC(=O)c1cnn2cc(Nc3ccccc3)c(NCc3cc(F)cnc3O[C@@H](C)CNC(=O)OC(C)(C)C)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK2 Q9HBH9 5/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ EGFR P00533 1/20 0.33
▸ ERBB2 P04626 1/20 0.33
▸ PCSK9 Q8NBP7 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ SIRT5 Q9NXA8 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ HTT P42858 2/20 0.32
▸ MAP2K1 Q02750 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25117920 0.90 JAK2 (0.36) MKNK2JAK2NTRK1ADORA3ADORA2A
SCHEMBL25117922 0.90 JAK2 (0.36) MKNK2JAK2NTRK1ADORA3ADORA2A
SCHEMBL25117792 0.88 JAK2 (0.35) MKNK2JAK2NTRK1ADORA3ADORA2A
SCHEMBL25117793 0.85 JAK2 (0.35) JAK2NTRK1ADORA3ADORA2AHTT
SCHEMBL25118097 0.84 RAF1 (0.37) JAK2NTRK1ADORA3ADORA2AHSD17B10
SCHEMBL25118098 0.84 RAF1 (0.37) JAK2NTRK1ADORA3ADORA2AHSD17B10
SCHEMBL25839410 0.84 JAK2 (0.34) MKNK2JAK2NTRK1ADORA3ADORA2A
SCHEMBL25117961 0.82 CCNA2 (0.37) ADORA3ADORA2AEGFRERBB2PCSK9
SCHEMBL25117959 0.82 CCNA2 (0.37) ADORA3ADORA2AEGFRERBB2PCSK9
SCHEMBL25839421 0.82 KDM4E (0.39) MKNK2ADORA3ADORA2ATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 — — US disclosed
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD (CN) 2023-07-13 — — US disclosed
EP-4163283-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF Scinnohub Pharmaceutical Co., Ltd (CN) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219978-A1 COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF BTK, SRC, YES1 MKNK2 711/4885JAK2 9/4885NTRK1 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback